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ABSTRACT
Regulated expression of a therapeutic gene is crucial
forsafeand efficaciousgenetherapy.Manyinducible
regulatory systems use a constitutive promoter to
express a regulatory protein, such as rtTA in the
Tet-On system, which may restrict their use because
of cytotoxicity and immunogenicity. Autoregulatory
expression of rtTA provides extremely low levels of
rtTA when transgene expression is off, with rapid
transgene induction upon addition of doxycycline.
Lentiviralvectorsefficientlytransfergenestodividing
and non-dividing cells with long-term gene expres-
sionbothinvitroandinvivo.Wecomparedregulatory
function in a single lentiviral vector where rtTA was
either expressed from a constitutive promoter or
placed in an autoregulatory loop. Autoregulatory
expression of rtTA was superior to constitutive pro-
moter expression, resulting in higher viral titers,
undetectable levels of both rtTA and transgene
expression in the absence of doxycycline, improved
induction kinetics and increased induction levels in
all cells tested. We further expanded the utility of the
autoregulatoryvectorbyusinganimprovedrtTAvari-
ant with an increased sensitivity to doxycycline. This
lentiviral vector with doxycycline-regulated trans-
gene expression may be useful for gene therapy
applicationsandinexperimentalsettingswherestrict
temporal expression of a transgene is required.
INTRODUCTION
Lentiviral vectors are efﬁcient vehicles for the delivery of
genes to both dividing and non-dividing cells in vitro and
in vivo (1–3). Many vectors for gene therapy use a strong
constitutive promoter to drive the expression of the transgene,
which may not reﬂect physiological expression levels and can
in fact be harmful to the cell (4,5). Progress toward the clinical
use of lentiviral vectors for gene therapy will require the
ability to regulate the expressionof the transgene for improved
safety and efﬁcacy (4,5). An ideal gene therapy vector should
include a regulatory system that is off in the resting state,
exhibit tight regulation and allow for rapid and repeatable
induction in response to a clinically approved inducer
molecule.
The tetracycline-dependent transcriptional regulatory sys-
tem (6) is one of the best studied systems with proven efﬁcacy
in vitro and in vivo (4,5,7,8). This system is based on the
Escherichia coli Tn10 Tetracycline resistance operator con-
sisting of the tetracycline repressor protein (TetR) and a spe-
ciﬁc DNA-binding site, the tetracycline operator sequence
(TetO). In the absence of tetracycline, TetR dimerizes and
binds to the TetO. Tetracycline or doxycycline (a tetracycline
derivative)canbindand inducea conformationalchange inthe
TetR leading to its disassociation from the TetO. A TetR
mutant was identiﬁed with a reverse phenotype where binding
to the TetO was triggered by doxycycline (9). Fusion of the
VP16 transactivation domain of the Herpes simplex virus to
either TetR or the mutant TetR resulted in a tetracycline
responsive transactivator (tTA) (6) and a reverse tTA (rtTA)
(9). Mutagenesis and codon optimization of the TetR and
reduction of the VP16 activation domain to three repeats of
a 12 amino acid minimal activation domain (10) generated an
improved rtTA, rtTA2
S-S2 (11), with reduced background
activity. A tetracycline responsive promoter (TRE) for
mammalian expression was constructed by fusing a minimal
cytomegalovirus (CMV) promoter to seven TetO repeats
(6), which was combined with either tTA to make the
Tet-Off or rtTA to make the Tet-On transcriptional regulatory
system.
Although the Tet-Off system is more sensitive to doxycyc-
line asopposedtothe Tet-On system, there are several features
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doi:10.1093/nar/gni062that make the Tet-Off system less suitable for gene therapy
applications. Inductionwiththe Tet-Off systemdependsonthe
pharmacological elimination of doxycycline and tends to be
slower as compared with the Tet-On system (9,12,13). In
addition, the Tet-Off system requires persistent administration
of doxycycline to suppress gene expression, which may not be
ideal when used with a lentiviral vector that provides life long
gene expression. These properties make the Tet-On system a
better choice for transcriptional regulation in most gene ther-
apy applications. Recent improvements in the rtTA protein
(11,14), including reduced background activity and increased
doxycycline sensitivity, now make this possible.
Many Tet-On regulated transgene expression systems use
two separate constructs, one containing the TRE-regulated
transgene and the second containing rtTA expressed by a
constitutive promoter. This binary system relies on the
co-transduction of cells and requires selection and screening
to obtain a homogenously transduced population, which is not
possible in vivo. We have combined all the elements required
for Tet-On regulation into a single cassette with either a con-
stitutive promoter or an autoregulatory loop for the expression
of rtTA. These cassettes were cloned into a third generation
lentiviral vector system for the production of self-inactivating
vectors (15,16) containing the central polypurine tract (cPPT)
and the Hepatitis B post-transcriptional regulatory element
(PRE) for enhanced gene expression (17).
A limited number of studies have evaluated the autoregu-
latory expression of rtTA in a plasmid (18,19) and AAV
vector (20) as compared with tTA (21–26). Autoregulatory
expression of rtTA allows for extremely low levels of both
the transactivator and the transgene product in the absence of
doxycycline, with sufﬁcient rtTA molecules for initiating the
expression upon addition of doxycycline. Restricted expres-
sion of rtTA with an autoregulatory system could expand
applicability both in vitro and possibly in vivo. Previous
studies of autoregulatory rtTA expression were performed
with transient vector systems (18–20) that remain episomal.
In contrast, lentiviral vector gene transfer results in stable
integration and long-term gene expression, which presents a
different context for the evaluation of autoregulatory rtTA
expression. Our aim is to compare transcriptional regulatory
function between a constitutive promoter and an autoregu-
latory loop driving expression of rtTA in a single lentiviral
vector. Optimization of the lentiviral vector constructs was
performed for the production of high titer regulatable len-
tiviral vectors. We tested this vector system in a panel of
human primary and established cell lines of diverse origin.
We further compared rtTA protein expression, repeated in-
duction cycles, induction kinetics and doxycycline
concentration-dependent expression in single Tet-On len-
tiviral vectors with a constitutive promoter or an autoregu-
latory loop for the expression of rtTA.
MATERIALS AND METHODS
Cloning of the constructs
First generation vectors were adapted from a conditional rep-
licating HIV-1 vector (27). The viral LTR containing eight
copies of the TetO and rtTA was cloned as a partial AﬂII and
EcoRI fragment and cloned into pRRL cPPT PGK eGFP PRE
SIN (17) to make LTRCMVAR2. The EMCV IRES fragment
was cloned by PCR into the pCR2.1 TOPO vector using the
following primers and sequence veriﬁed.
IRES S
50-ATCCGCGGACCGGTACGTACTCGAGGCTGCAG-
GAATTCCGCCCC-30
IRES AS
50-TTGTCCAGTCTAGACATGGTTGTGGCCATATTA-
TCATCGTG-30
TheCMVpromoterfromLTRConAR2wasremovedbyXbaI–
SacII digestion. An XbaI–SacII digest of pCR2.1 IRES
released the internal ribosome entry site (IRES) for ligation
into LTRCMVAR2 to make LTRAutoAR2. A BamHI–EcoRI
digest of pd2eGFP (28) created a d2eGFP fragment that was
cloned into LTRAutoAR2 to make LTRAutoR2. An AgeI–
EcoRI digest of pd2eGFP created a d2eGFP fragment that was
ligated into LTRConAR2 to make LTRConR2.
pRRL cPPT d2eGFP CMV rtTA2
S-S2 LTRTetO8 SIN
(LTRCMVR2)
pRRL cPPT d2eGFP IRES rtTA2
S-S2 LTRTetO8 SIN
(LTRAutoR2)
An AgeI digest of LTRAutoR2 removed d2eGFP and the
subsequent ligation created LTRMCSAutoR2. Digestion of
pCMV-rtTAS12G F86Y A209T (14) (rtTA3) with XbaI–XmaI
created an rtTA3 fragment that was ligated into an XbaI–
XmaI digest of LTRMCSAutoR2 to make LTRMCSAutoR3.
pRRL cPPT TRE d2eGFP CMV rtTA2
S-S2 PRE LTR SIN
(TRECMVR2)
pRRL cPPT TRE d2eGFP IRES rtTA2
S-S2 PRE LTR SIN
(TREAutoR2)
pRRL cPPT TRE d2eGFP IRES rtTA3 PRE LTR SIN
(TREAutoR3)
The CMVR2 and AutoR2 fragments were created by a
BamHI–EcoRV digest of LTRCMVR2 and LTRAutoR2,
respectively. The pUHV13-3wt4c vector containing CMVmin
fused to seven copies of the TetO was also digested with
BamHI–EcoRV to remove luciferase. The CMVR2 and
AutoR2 fragments were ligated to create TRECMVA and
TREAutoA. An XhoI site 50 of the TRE was replaced by a
ClaI site. A ClaI–DraI digest of both TREAutoB and
TRECMVB released the complete Tet-On Auto and CMV
cassettes, respectively, which were subcloned into a ClaI–
EcoRv digested pBSK vector to make pBTREAutoB and
pBTRECMVB. The Tet-On Auto and CMV cassettes were
released by a ClaI–SpeI digest and ligated into a ClaI–SpeI
digested lentiviral vector backbone to make TREAutoR2 and
TRECMVR2. An AgeI–EcoRv digest of LTRAutoR3 released
the Tet-On Auto fragment with rtTA3. The fragment was
cloned into an AgeI–AscI (blunted) digest of TREAutoR2
to create TREAutoR3.
Cell lines and culturing
The following cell lines and primary cells were used in this
study: HEK293T, HeLa, HepG2, SJNB-8 (neuroblastoma),
human umbilical vein endothelial cells (HUVECs), human
ﬁbroblasts and human fetal liver cells (HFLCs). All cells
were cultured (with the exception of HUVEC and HFLC)
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serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin
and 2 mM glutamine at 37 Ci n1 0 %C O 2.
HFLC cells were cultured in standard DMEM, above,
supplemented with 100 nM dexamethasome and 1· ITS
mix (Invitrogen).
HUVEC cells were cultured in M199 with 25 mM HEPES
(Gibco) supplemented with 10% FBS, 100 U/ml penicillin,
100 mg/ml streptomycin, 2 mM glutamine, 50 mg/ml
heparin and 25 mg/ml endothelial cell growth supplement
(Sigma). Cells were cultured on ﬁbronectin coated ﬂasks
and plates.
Lentiviral vector preparation
Lentiviral vectors were prepared as reported previously (29).
Brieﬂy, HEK 293T cells were transiently transfected by cal-
cium phosphate precipitation with a third generation lentiviral
vector system (15,16). Twenty-four hours following transfec-
tion, fresh medium was added supplemented with 25 mM
HEPES, pH 7.4. Virus containing supernatant was collected
48 hfollowing transfection, ﬁltered through 0.45 mm Millipore
ﬁlters and frozen at  80 C.
Virus titer determination and cell transduction
Viraltiterswere determinedby serialdilution ofvirusonHeLa
cells transduced for 4 h with 10 mg/ml DEAE Dextran.
Doxycycline (Sigma) was dissolved at 10 mg/ml in water
and ﬁlter-sterilized. Stocks were kept frozen at  20 C.
Doxycycline (1000 ng/ml) was added to cells for 72 h and
cells were harvested and green ﬂuorescent protein (GFP)
expression was measured by ﬂow cytometry. For all experi-
ments, induction was performed with 1000 ng/ml doxycycline
unless otherwise speciﬁed.
SDS–PAGE and western blotting
Cells were harvested by washing with phosphate-buffered
saline (PBS) and collected by scraping in PBS with 5 mM
EDTA. Lysates were made by sonication in PBS with 5 mM
EDTA. Protein levels were determined using the Bio-Rad DC
Protein Assay. An aliquot of 25 mg of total protein was loaded
for each lysate on NuPage gels (10% Bis-Tris with MOPS
running buffer; Invitrogen) according to the manufacturer’s
instructions. Gel and western blotting was performed in an
Xcell SureLock Mini-Cell (Invitrogen) following the manu-
facturer’s instructions.
An antibody directed against rtTA was purchased from
MoBiTec (TET02) and used at a dilution of 1:2000. A mono-
clonal antibody directed against eGFP was purchased from
Clontech (JL-8) and used at a dilution of 1:5000. A mono-
clonal antibody directed against actin was purchased from
NeoMarkers (Ab-5) and used at a dilution of 1:1000. Goat
anti-mouse IgG (H + L)–horseradish peroxidase conjugate
(Bio-Rad) was used at a 1:1000 dilution. Lumi-Light western
blotting substrate (Roche) was used for the detection of bands
and the blot was scanned in using a LumiImager F1 and
LumiAnalyst 3.1 software (Roche).
RESULTS
Generation of lentiviral vector constructs
In all our constructs, we used a destabilized form of GFP
(d2eGFP, 2 h half-life) (28) speciﬁcally designed for use
with transcriptional regulatory systems. Our ﬁrst generation
single Tet-On lentiviral vectors, LTRCMVR2 (a constitutive
CMV promoter driving rtTA expression) and LTRAutoR2
(autoregulatory rtTA expression), contain the TetO element
within the vector LTR (27) (Figure 1A and B). These con-
structs yielded viral titers  100 times lower when compared
with lentiviral vectors expressing GFP from a constitutive
promoter (Table 1) and were, therefore, not considered for
Figure 1. (A) Schematic representation of the constructed lentiviral vectors. First generation single dox-regulated lentiviral vector with eight repeats of the TetO
located within the viral LTR with rtTA expressed from the strong constitutively active CMV promoter LTRCMVR2 (A) or rtTA expressed as a bicistronic mRNA
LTRAutoR2 (B). Second generation single dox-regulated lentiviral vector with an internal tetracycline responsive element (TRE) containing a minimal CMV
promoter fused to seven copies of the TetO and the HBV PRE with rtTA expressed from the strong constitutively active CMV promoter TRECMVR2 (C) or rtTA
expressed as a bicistronic mRNA TREAutoR2 (D). Asterisk: rtTA was either rtTA2
S-S2 or rtTA3 (rtTA2
S-S2 with three amino acid substitutions S12G, F86Y and
A209T).
Table 1. Viral titers reported as HeLa transducing units (HTU/ml)
Lentiviral vector HTU/ml
PGKeGFP 2.5 · 10
6 – 3.3 · 10
5
LTRCMVR2 1.6 · 10
4 – 1.3 · 10
4
LTRAutoR2 4.2 · 10
3 – 8.5 · 10
2
TRECMVR2 2.2 · 10
5 – 1.4 · 10
5
TREAutoR2 1.0 · 10
6 – 2.5 · 10
5
TREAutoR3 1.3 · 10
6 – 3.7 · 10
5
PGKeGFP is a lentiviral vector with constitutive expression of eGFP using the
PGK promoter. Mean and standard deviations were determined from at least
three independent virus preparations.
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constitutive CMV promoter driving rtTA expression) and TR-
EAutoR2 (autoregulatory rtTA expression) (Figure 1C and D),
we introduced two improvements over the ﬁrst generation.
First, the TetO element (TRE) was removed from the
LTR and internalized in the vector. Second, to enhance the
gene expression, the Hepatitis B post-transcriptional regulat-
ory element was added 30 of the expression cassette. Only
TREAutoR2 and TREAutoR3 yielded viral titers comparable
with a lentiviral vector with constitutive expression of
GFP (Table 1).
Autoregulatory expression of rtTA results in higher
induction levels
For a comprehensive analysis of the induction levels of both
TRECMVR2 and TREAutoR2, we chose a panel of human
primary and established cell lines derived from a variety of
tissues. Each cell line was transduced at a multiplicity of
infection (MOI) of 1, induced with 1000 ng/ml doxycycline
for 72 h and harvested for ﬂow cytometry analysis. Analysis
was performed on the whole population of transduced cells to
avoid bias from clonal selection. We observed superior gene
induction in all cell lines transduced with TREAutoR2 com-
pared with TRECMVR2 (Table 2). Primary human ﬁbroblasts
provided the highest induction levels for both TRECMVR2
and TREAutoR2 (Table 2). The primary cells, ﬁbroblasts,
HUVEC, and HFLC and the cell line SJNB-8, gave approx-
imately equal percentage of GFP positive cells with TRE-
ConR2 and TREAutoR2 (Table 2). In contrast, we observed
a higher percentage of GFP positive cells with TREAutoR2
(Table 2) in the 293T, HeLa and HepG2 cell lines. Together
these data show that the autoregulatory expression of rtTA
improves the induction levels in all cells tested and may lead
to an improvement in the transduction efﬁciency in certain
cell types.
Table2.InductionlevelsandpercentageofGFPpositivecellsonindicatedcell
lines transduced at an MOI of 1 with either TRECMVR2 or TREAutoR2
lentiviral vectors
Cell type Virus Induction Percentage of GFP
positive cells
HUVEC TRECMVR2 11.35 – 3.91 55.02 – 34.14
TREAutoR2 32.97 – 19.46 68.33 – 33.39
Fibroblast TRECMVR2 22.32 – 2.67 83.95 – 7.75
TREAutoR2 49.47 – 6.87 93.77 – 2.89
HFLC TRECMVR2 6.46 – 0.85 48.62 – 22.83
TREAutoR2 28.89 – 13.54 49.92 – 20.36
293T TRECMVR2 10.44 – 1.21 34.48 – 5.98
TREAutoR2 17.21 – 1.42 71.07 – 11.95
HeLa TRECMVR2 13.23 – 2.40 49.60 – 11.14
TREAutoR2 48.84 – 20.04 88.73 – 3.04
HepG2 TRECMVR2 3.81 – 0.86 36.23 – 6.58
TREAutoR2 26.94 – 11.72 68.97 – 13.31
SJNB-8 TRECMVR2 4.22 – 0.50 31.62 – 5.33
TREAutoR2 14.59 – 1.65 31.80 – 4.77
Inductionvalueswerecalculatedbydividingthemeanfluorescenceofd2eGFP
expression with doxycycline by the mean fluorescence without doxycycline.
Primary cell lines are HUVEC, human skin fibroblasts and HFLC. Established
cell lines are 293T HEK (human embryonic kidney), HeLa (cervical carci-
noma), HepG2 (hepatoma) and SJNB-8 (neuroblastoma). Induction values
and percentage of GFP positive cells represent three independent experiments
performed in duplicate.
B A
Figure 2. (A) Immunoblots of primary human fibroblasts lysates transduced with the indicated lentiviral vectors: lane 1, non-transduced cells; lane 2, PGKeGFP;
lanes3and4,TRECMVR2;lanes5and6,TREAutoR2.Priortoharvestingcellsweregrowneitherintheabsence( )orpresence(+)ofdoxycycline(1000ng/ml)for
72 h. Separate immunoblots were probed with an antibody directed against either rtTA, GFP or actin. (B) Representative flow cytometry histograms of primary
human fibroblasts transduced at an MOI of 1 with TRECMVR2 and TREAutoR2 in the absence and presence of doxycycline.
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expression
Autoregulatory expression of rtTA was expected to result in a
low basal expression ofboth rtTAand transgeneinthe absence
of doxycycline. To conﬁrm this, primary human ﬁbroblasts
were transduced at an MOI of 1 with either TRECMVR2 or
TREAutoR2. Following expansion, the cells were cultured
with or without doxycycline at 1000 ng/ml for 72 h and
then harvested. In the untreated cell lysates of TREAutoR2
transduced cells, we were unable to detect the expression of
rtTA and d2eGFP by western blotting (Figure 2A, lane 5),
conﬁrming that the basal expression of rtTA was extremely
low. Following addition of doxycycline, we observed pro-
found induction of rtTA and d2eGFP (Figure 2A, lane 6).
The destabilized GFP, d2eGFP, has a C-terminal fusion
from the C-terminus of the mouse ornithine decarboxylase
protein (28) resulting in the observed retarded migration
(Figure 2A lane 2 versus lanes 4 and 6). TRECMVR2-
transduced ﬁbroblasts expressed a signiﬁcant amount of
rtTA protein in the absence of doxycycline (Figure 2A,
lane 3). Interestingly, we observed an increase in the rtTA
expression with TREConR2 following addition of doxycyc-
line (Figure 2A, lane 4), which is probably a result of
transcriptional read-through or promoter interference. Repres-
entative ﬂow cytometry histograms of primary human ﬁbro-
blasts transduced at an MOI of 1 with either TRECMVR2 or
TREAutoR2 grown in the absence or presence of doxycycline
further demonstrate the superior regulation and induction of
TREAutoR2 (Figure 2B). The immunoblotting and ﬂow cyto-
metry results validate that TREAutoR2 allows for the regu-
lated expression of both rtTA2
S-S2 and d2eGFP.
A constitutive promoter expression of rtTA
results in a loss of transduced cells following
repeating induction cycles
Repeated induction cycles may be required for many gene
therapy and gene function applications. A constitutive pro-
moter driving expression of rtTA may be detrimental, particu-
larly when transgene expression is not induced owing to
cytotoxic, anti-proliferative and immunogenic properties of
rtTA. We, therefore, performed repeated induction cycles in
HeLa cells transduced with either TRECMVR2 or TREAu-
toR2 to evaluate the relative effects on cell proliferation and
toxicity. HeLa cells were transduced at a low MOI of 0.1 with
either TRECMVR2, TREAutoR2 or a control lentiviral vector
PGKeGFP expressing GFP from the PGK promoter. In one
induction cycle, transduced cells were grown in the presence
of doxycycline for 72 h, passaged and grown without doxy-
cycline for 96 h. We set the percentage of GFP positive cells
following the ﬁrst induction cycle to 100% and subsequent
induction cycles are presented relative to this value. The per-
centage of GFP positive cells transduced with the control
lentiviral vector remained unchanged for the duration of the
study (Figure 3). The percentage of GFP positive cells
transduced with TREConR2 decreased by more than 50%
after a single induction cycle and fell to 20% of the starting
value after repeated cycles. In contrast, the percentage of
TREAutoR2-transduced cells remained unchanged even
after four induction cycles (Figure 3). Only when
TREAutoR2-transduced HeLa cells were grown continuously
in the presence of doxycycline, we observed a similar reduc-
tion in the relative amount of GFP positive cells (data not
shown). These results indicate that high levels of rtTA protein
obtained with a strong constitutive promoter driving rtTA
expression or a continuously activated autoregulatory loop
may decrease cell proliferation or is cytotoxic.
Rapid induction with the autoregulated rtTA lentiviral
vector
An effective transcriptional regulatory system should be rap-
idly turned on following the administration of the inducer
molecule. The low basal expression of rtTA2
S-S2 from
TREAutoR2 in the absence of doxycycline could increase
the time required for maximal activation as compared with
TRECMVR2. To determine the time for maximal induction,
we transduced HeLa cells at an MOI of 1 with either
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Figure 4. Induction kinetics of HeLa cells transduced at an MOI of 1 with
TRECMVR2 or TREAutoR2. Percentage of maximum expression at indicated
time points following doxycycline administration. Values represent the mean
and standard deviation of three independent experiments performed in
duplicate.
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Figure 3. CyclicinductionwithserialpassagingofHeLacellstransducedatan
MOIof0.1withPGKeGFP,TRECMVR2orTREAutoR2.ThenumberofGFP
positivecellsdetecteduponfirst inductionwasset to100%withall subsequent
measurements normalized to the first induction levels. Cells were cultured
for 3 days with doxycycline and the percentage of GFP positive cells was
determined by flow cytometry. Subsequently, the cells were passaged and
cultured for 4 days without doxycycline. A new induction cycle was initiated
bypassagingthecellsandtheadditionofdoxycycline.Thesedataarefromthree
independent experiments performed in duplicate with mean and standard
deviations.
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B
Figure 5. Doxycyclinedose–response onprimaryhumanfibroblaststransducedatanMOI0.1 withTRECMVR2,TREAutoR2orTREAutoR3.(A) Representative
flow cytometry histograms of primary human fibroblasts transduced with indicated virus and treated with either 0, 100 or 1000 ng/ml doxycycline. (B) Mean
fluorescentintensityoffibroblaststreated with0, 25,50,100,500or1000ng/mldoxycyclinetransducedwithindicatedinduciblelentiviralvector.Closedtriangles
representTRECMVR2;opensquaresrepresentTREAutoR2;andcloseddiamondsrepresentTREAutoR3.Valuesrepresentthemeanandstandarddeviationoftwo
independent experiments performed in duplicate.
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time points. We set 72 h as the time required for maximal
expression because we observed no further increase in GFP
expression at later time points (D.M. Markusic, unpublished
data). Maximum gene expression of d2eGFP was obtained
with TREAutoR2 at 48 h as compared with TREConR2 at
72 h (Figure 4). Thus, in addition to higher induction levels,
TREAutoR2 also triggers a more rapid gene induction than
TRECMVR2.
The autoregulated lentiviral vector is greatly improved
with a more sensitive rtTA variant
The development of a lentiviral vector with regulated trans-
gene expression for use in gene therapy requires complete
gene control at physiological obtainable concentrations of
doxycycline. We compared the level of d2eGFP expression
of TRECMVR2 and TREAutoR2on primary ﬁbroblasts over a
range of doxycycline concentrations (0–1000 ng/ml). Low
doxycycline concentrations did not activate d2eGFP expres-
sion with TREAutoR2 (Figure 5A and B). The very low basal
expression of rtTA2
S-S2 and low sensitivity to doxycycline
probably prevents the successful initiation of the autoregulat-
ory loop. To increase doxycycline sensitivity, we replaced
rtTA2
S-S2 with the recently described improved rtTA3 variant
with improved activity and doxycycline sensitivity (14). Sub-
stitution of rtTA3 into TREAutoR2 to make TREAutoR3 res-
ulted in viral titers similar to TREAutoR2 (Table 1) and
activation of the autoregulatory loop and gene expression at
a lower concentration of doxycycline (Figure 5A and B).
Furthermore, at 100 ng/ml doxycycline TREAutoR3 reached
expression levels 4-fold higher than TREConR2 and 7-fold
higher than TREAutoR2, and at 1000 ng/ml doxycycline both
TREAutoR2 and TREAutoR3 reached expression levels
higher than TRECMVR2.
DISCUSSION
We report a single Tet-On lentiviral vector with autoregulated
rtTA expression for regulated expression of a transgene.
Previous studies using autoregulation of tTA or rtTA tested
the addition of a second TRE (18,24) or a bi-directional TRE
(19,20,25). When the strong TRE promoter was used to drive
the expression of tTA or rtTA, cytotoxicity (19,24) and
reduced cell proliferation (30) were reported. To reduce the
efﬁciency of rtTA expression, we used a bicistronic mRNA
that expresses both the transgene and rtTA via an IRES (31)
(Figure 1D). Previous studies using a bicistronic mRNA for
autoregulatory expression were performed in a single cell line
with the Tet-Off system (tTA) in a retroviral vector backbone
(21,22). These studies used either drug selection or cell sorting
to isolate cell clones that exhibit optimal induction and regu-
lation, which leads to bias and overestimation of regulatory
function as compared with the evaluation on a population of
transduced cells. Our Tet-On lentiviral vector with auto-
regulated rtTA expression further allows for efﬁcient gene
transfer tonon-dividing cells, does not require persistent doxy-
cycline administrationto switch off the gene expression, and is
better suited for gene therapy and a variety of gene function
applications.
We compared lentiviral vectors in which rtTA is expressed
from a constitutive promoter with vectors in which rtTA is
placed in an autoregulatory loop. Autoregulatory expression
of rtTA (TREAutoR2 and TREAutoR3) resulted in higher
lentiviral vector titers as compared with the constitutive
promoter expression vector (TRECMVR2) (Table 1). The
autoregulatory vector TREAutoR2 also provided superior in-
duction levels on a panel of human primary and established
cells lines (Table 2), which is consistent with previous ﬁndings
with the Tet-Off system (24). The variable induction levels
observed with the different cell lines can be attributed to
relative differences in transduction efﬁciencies or perhaps
relative sensitivity to the cytotoxic effects of rtTA. With
two established cell lines commonly used in our laboratory,
Caco-2 (a coloncarcinoma cell line) and CC-LP-1 (32)
(a cholangiocarcinoma cell line), we observed cytotoxicity
when cells were transduced with TREConR2 in the absence
or presence of doxycycline and with TREAutoR2 only when
doxycycline was present (data not shown). These ﬁndings
further demonstrate the very low basal expression of rtTA
in the absence of doxycycline obtained with TREAutoR2
and suggest that rtTA may not be compatible with all cell
types in vitro.
We demonstrated with immunoblotting that there was no
detectable level of rtTA expression with TREAutoR2 in the
absence of doxycycline, and transgene expression was rapidly
induced following addition of doxycycline (Figure 2A and B).
Repeated cycles of gene induction and expansion of HeLa
cells transduced with TRECMVR2 resulted in a loss of
GFP expressing cells over time, suggesting that a strong con-
stitutive promoter driving expression of rtTA may result in
decreased cell proliferation or cytotoxicity (Figure 3). This
was not observed when HeLa cells were transduced with
TREAutoR2 or a control lentiviral vector expressing GFP
from the PGK promoter. We, therefore, demonstrated that
TREAutoR2 is superior over TRECMVR2 for long-term cul-
turing with repeated induction cycles. The TREAutoR2 len-
tiviral vector resulted in superior induction kinetics over
TRECMVR2 (Figure 4). With TREAutoR2, rtTA is able to
activate its own promoter upon doxycycline administration
resulting in a rapid increase in the level of rtTA protein,
which leads to the strong and rapid induction in transgene
expression. One disadvantage of TREAutoR2 was the require-
ment for high concentrations of doxycycline to turn on gene
expression, which may not be possible to obtain in vivo.
By substituting rtTA2s-S2 with a greatly improved rtTA
variant (14), rtTA3, we were able to signiﬁcantly reduce
the concentration of doxycycline required for activation
(Figure 5A and B).
This is the ﬁrst comprehensive study comparing gene
regulation with constitutive or autoregulatory expression of
rtTA in the context of a single lentiviral vector system. Single
lentiviral vectors with doxycycline regulated gene expression
have been described with tTA (33–35) and rtTA (36). All of
these vectors used a strong constitutive promoter to express
either tTA or rtTA. Our results indicate that the autoregulatory
expression of rtTA creates an improved transcriptional
regulatory system with expanded applications in vitro and may
be more effective in vivo as compared with the constitutive
expression of rtTA. The Tet-On system with autoregulatory
rtTA expression in a single lentiviral vector is well suited for
a variety of applications, including gene therapy, generation
of transgenic animals, conditional immortalization and in
PAGE 7 OF 8 Nucleic Acids Research, 2005, Vol. 33, No. 6 e63research applications where strict temporal gene expression is
required.
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